“Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate to Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s143, https://doi.org/10.25251/skin.7.supp.143.